<p>JonesTrading 分析师 Justin Walsh 重申了对 PRAX 股票的看涨态度，今天给予了买入评级。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
<p>Justin Walsh 给予买入评级是基于与 Praxis Precision Medicines 癫痫产品组合相关的多种因素。最近在 2025 年美国癫痫学会年会上发布的临床更新突出了显著的进展，特别是关于 relutrigine 的 EMBOLD 试验，该试验因其疗效而提前停止。试验结果显示，安慰剂调整后的癫痫发作减少显著，且患者无运动性癫痫发作的天数增加，临床医生和护理人员对患者改善的反馈积极。</p>
<p>此外，vormatrigine 的 RADIANT 试验结果也令人鼓舞，表明其作为最佳抗癫痫药物的潜力。vormatrigine 显示出显著的癫痫发作减少，且相当一部分患者在无需调整剂量的情况下实现了发作自由。该药物还显示出良好的相互作用特征，适合多药物方案。凭借这些令人鼓舞的结果和即将发布的关键研究数据，Walsh 认为 Praxis Precision Medicines 的资产有强大的潜力惠及广泛的患者群体，从而证明了买入评级的合理性。</p>
<p>在今天发布的另一份报告中，Guggenheim 也重申了对该股票的买入评级，目标价为 760.00 美元。</p>

PRAX

<p>JonesTrading 分析师 Justin Walsh 重申了对 Praxis Precision Medicines 的买入评级，原因是其癫痫药物组合的进展令人鼓舞。relutrigine 的 EMBOLD 试验显示出显著的疗效，导致提前终止，而 vormatrigine 的 RADIANT 试验则表明其作为一种顶级抗癫痫药物的潜力。Guggenheim 也维持了买入评级，目标价为 760 美元，强调了 Praxis 的资产对患者的强大潜力</p>

<p>JonesTrading analyst Justin Walsh has reiterated their bullish stance on PRAX stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>JonesTrading 分析师 Justin Walsh 重申了对 PRAX 股票的看涨态度，今天给予了买入评级。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据，现在也享受 60% 的折扣。</li>
</ul>
</div><p>Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Praxis Precision Medicines’ epilepsy portfolio. The recent clinical update at the 2025 American Epilepsy Society Annual Meeting highlighted significant advancements, particularly with the EMBOLD trial of relutrigine, which was stopped early due to its efficacy. The trial results showed a notable placebo-adjusted seizure reduction and an increase in motor seizure-free days, with positive feedback from clinicians and caregivers regarding patient improvement.</p>
<div class="lb-trans"><p>Justin Walsh 给予买入评级是基于与 Praxis Precision Medicines 癫痫产品组合相关的多种因素。最近在 2025 年美国癫痫学会年会上发布的临床更新突出了显著的进展，特别是关于 relutrigine 的 EMBOLD 试验，该试验因其疗效而提前停止。试验结果显示，安慰剂调整后的癫痫发作减少显著，且患者无运动性癫痫发作的天数增加，临床医生和护理人员对患者改善的反馈积极。</p>
</div><p>Additionally, the RADIANT trial results for vormatrigine were promising, indicating its potential as a best-in-disease antiseizure medication. Vormatrigine demonstrated a significant reduction in seizures, with a substantial portion of patients achieving seizure freedom without the need for titration. The drug also showed a favorable interaction profile, making it suitable for multi-drug regimens. With these encouraging outcomes and upcoming pivotal study data, Walsh sees strong potential for Praxis Precision Medicines’ assets to benefit a wide range of patients, justifying the Buy rating.</p>
<div class="lb-trans"><p>此外，vormatrigine 的 RADIANT 试验结果也令人鼓舞，表明其作为最佳抗癫痫药物的潜力。vormatrigine 显示出显著的癫痫发作减少，且相当一部分患者在无需调整剂量的情况下实现了发作自由。该药物还显示出良好的相互作用特征，适合多药物方案。凭借这些令人鼓舞的结果和即将发布的关键研究数据，Walsh 认为 Praxis Precision Medicines 的资产有强大的潜力惠及广泛的患者群体，从而证明了买入评级的合理性。</p>
</div><p>In another report released today, Guggenheim also reiterated a Buy rating on the stock with a $760.00 price target.</p>
<div class="lb-trans"><p>在今天发布的另一份报告中，Guggenheim 也重申了对该股票的买入评级，目标价为 760.00 美元。</p>
</div>

Praxis Precision Medicines：有前景的癫痫产品组合的进展证明了买入评级的合理性